KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Travere Therapeutics (TVTX) EBITDA Margin: 2011-2025

Historic EBITDA Margin for Travere Therapeutics (TVTX) over the last 12 years, with Sep 2025 value amounting to 15.45%.

  • Travere Therapeutics' EBITDA Margin rose 10161.00% to 15.45% in Q3 2025 from the same period last year, while for Sep 2025 it was -20.32%, marking a year-over-year increase of 15113.00%. This contributed to the annual value of -137.31% for FY2024, which is 6161.00% down from last year.
  • Travere Therapeutics' EBITDA Margin amounted to 15.45% in Q3 2025, which was up 238.93% from -11.12% recorded in Q2 2025.
  • Travere Therapeutics' EBITDA Margin's 5-year high stood at 406.89% during Q3 2023, with a 5-year trough of -430.08% in Q4 2021.
  • Over the past 3 years, Travere Therapeutics' median EBITDA Margin value was -86.16% (recorded in 2024), while the average stood at -91.70%.
  • Per our database at Business Quant, Travere Therapeutics' EBITDA Margin spiked by 65,007bps in 2023 and then plummeted by 49,305bps in 2024.
  • Travere Therapeutics' EBITDA Margin (Quarterly) stood at -430.08% in 2021, then soared by 19,479bps to -235.29% in 2022, then skyrocketed by 4,005bps to -195.25% in 2023, then skyrocketed by 11,592bps to -79.33% in 2024, then soared by 10,161bps to 15.45% in 2025.
  • Its EBITDA Margin stands at 15.45% for Q3 2025, versus -11.12% for Q2 2025 and -51.37% for Q1 2025.